215
Participants
Start Date
February 16, 2016
Primary Completion Date
August 28, 2017
Study Completion Date
September 29, 2017
ASP7962
Participants receive ASP7962 100 mg orally twice daily, in the morning and evening with or without food (approximately 12 hours).
Naproxen
Participants receive naproxen 500 mg orally twice daily, in the morning and evening with or without food (approximately 12 hours).
Placebo
Participants receive matching placebo orally twice daily, in the morning and evening with or without food (approximately 12 hours).
Site HU36007, Budapest
Site BE32002, Merksem
Site HU36001, Esztergom
Site HU36003, Komárom
Site BE32003, Leuven
Site HU36006, Debrecen
Site DE49003, Leipzig
Site BE32004, Yvoir
Site HU36005, Békéscsaba
Site HU36002, Baja
Site HU36009, Szeged
Site ES34008, Barcelona
Site ES34012, Barcelona
Site HU36004, Veszprém
Site HU36008, Balatonfüred
Site DE49006, Berlin
Site CZ42002, Prague
Site CZ42005, Prague
Site ES34002, A Coruña
Site ES34004, Santiago de Compostela
Site ES34005, Madrid
Site DE49001, Magdeburg
Site ES34010, Valencia
Site ES34003, Bilbao
Site ES34001, Barakaldo
Site CZ42006, Hradec Králové
Site DE49004, Deggingen
Site DE49007, Bayern
Site DE49005, Munich
Site CZ42003, Kunovice
Site GB44006, London
Site GB44011, North Shields
Site GB44010, Oxfordshire
Site GB44012, West Midlands
Astellas Pharma Europe B.V.
INDUSTRY